All > Peritoneal Cancer > Recurrent Ovarian Cancer

Monoclonal Antibodies

Batiraxcept for Fallopian Tube Carcinoma

M D Anderson Cancer Center, Houston, TX

Targeting 9 different conditionsBatiraxcept +1 morePhase 1 & 2Waitlist AvailableLed by Amir A JazaeriResearch Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Life expectancy of >= 12 weeks

Be older than 18 years old

Must not have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Upup to 1 year

Awards & highlights

No Placebo-Only Group

All Individual Drugs Already Approved

Study Summary

This trial is testing the side effects and best dose of AVB-S6-500 in combination with durvalumab for patients with ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum therapy or has come back.

Eligible Conditions

Fallopian Tube Carcinoma
Peritoneal Carcinoma
Fallopian Tube Cancer
Ovarian Cancer

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below

Select...

You are expected to live for at least 12 more weeks.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of adverse events

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Arm II (durvalumab, batiraxcept)Experimental Treatment2 Interventions

Patients receive durvalumab IV over 60 minutes on days 1 and 22 of cycle 0 and on day 1 of subsequent cycles. Beginning cycle 1, patients also receive batiraxcept IV over 60 minutes on days 1 and 15. Cycle 0 continues for 6 weeks and subsequent cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Group II: Arm I (batiraxcept, durvalumab)Experimental Treatment2 Interventions

Patients receive batiraxcept IV over 60 minutes on days 1, 15, and 29 of cycle 0, and on days 1 and 15 of subsequent cycles. Beginning cycle 1, patients also receive durvalumab IV over 60 minutes on day 1. Cycle 0 continues for 6 weeks and subsequent cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Durvalumab

FDA approved

0 / 1Eligibility criteria met

Find a site

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,872 Previous Clinical Trials

1,781,448 Total Patients Enrolled

4 Trials studying Fallopian Tube Carcinoma

420 Patients Enrolled for Fallopian Tube Carcinoma

Aravive Biologics IncUNKNOWN

AstraZenecaIndustry Sponsor

4,118 Previous Clinical Trials

336,413,875 Total Patients Enrolled

Amir A JazaeriPrincipal Investigator

M.D. Anderson Cancer Center

6 Previous Clinical Trials

318 Total Patients Enrolled

Media Library

AVB-S6-500 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04019288 — Phase 1 & 2

AVB-S6-500 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04019288 — Phase 1 & 2

Fallopian Tube Carcinoma Research Study Groups: Arm I (batiraxcept, durvalumab), Arm II (durvalumab, batiraxcept)

Fallopian Tube Carcinoma Clinical Trial 2023: AVB-S6-500 Highlights & Side Effects. Trial Name: NCT04019288 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants have consented to this clinical trial?

"At present, this medical trial is not presently enrolling patients. The clinical trial was first listed on October 11th 2019 and the latest update occurred on December 8th 2022. There are currently 3693 studies recruiting for recurrent ovarian carcinoma, as well as 334 trials actively seeking participants to test out Batiraxcept."

Answered by AI

Have there been prior investigations utilizing Batiraxcept?

"Currently, there are 334 active clinical trials with 51 of those in the final Phase 3 stage. Although most studies for Batiraxcept originate from Nashville, Tennessee, this drug is being explored at 12994 different sites worldwide."

Answered by AI

How has Batiraxcept been implemented as a treatment option?

"Batiraxcept is a common treatment for stage 3 unresectable non-small cell lung cancer. Additionally, it has been employed to treat metastatic ureteral carcinoma and advanced directives."

Answered by AI

Are there any openings to participate in this experiment?

"Clinicaltrials.gov attests that the posted trial, which was established in October 2019 and updated last December, is not accepting applicants presently. However, there are still plenty of other medical trials available with 4027 being open for recruitment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

2019. "AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04019288.